Syncona Regulatory News (SYNC)

17 April 2024

Syncona Limited

("Syncona" or the "Company")

Transaction in Own Shares

Syncona, a leading healthcare company focused on creating, building and scaling global leaders in life science announces that, in accordance with the terms of its share buyback programme announced on 29 September 2023 (the "Share Buyback Programme"), the Company purchased the following number of its ordinary shares of no par value ("Ordinary Shares") each through Numis Securities Limited ("Numis").

The repurchased Ordinary Shares will be held by the Company in treasury. Following the purchase and settlement of these Ordinary Shares, the Company's issued ordinary share capital is 671,806,666 of which 18,011,080 Ordinary Shares will be held in treasury, which attract no voting rights. Therefore, the total voting rights in the Company will be 653,795,586. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Numis as part of the Share Buyback Programme.

Individual information:

For further information, please contact:

Syncona Ltd

Annabel Clark 

Tel: +44 (0) 7714 916615

Numis Securities Limited

Nathan Brown

Freddie Barnfield

Tel: +44 (0) 7260 1000